Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.
Miranda SoHelen TsaiNeeraja SwaminathanRachel BartashPublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2022)
Antimicrobial therapies are essential tools for transplant recipients who are at high risk for infectious complications. However, judicious use of antimicrobials is critical to preventing the development of antimicrobial resistance. Treatment of multidrug-resistant organisms is challenging and potentially leads to therapies with higher toxicities, intravenous access, and intensive drug monitoring for interactions. Antimicrobial stewardship programs are crucial in the prevention of antimicrobial resistance, though balancing these strategies with the need for early and frequent antibiotic therapy in these immunocompromised patients can be challenging. In this review, we summarize 5 frequently encountered transplant infectious disease stewardship challenges, and we suggest strategies to improve practices for each clinical syndrome. These 5 challenging areas are: asymptomatic bacteriuria in kidney transplant recipients, febrile neutropenia in hematopoietic stem cell transplantation, antifungal prophylaxis in liver and lung transplantation, treatment of left-ventricular assist device infections, and Clostridioides difficile infection in solid-organ and hematopoietic stem-cell transplant recipients. Common themes contributing to these challenges include limited data specific to transplant patients, shortcomings in diagnostic testing, and uncertainties in pharmacotherapy.
Keyphrases
- antimicrobial resistance
- infectious diseases
- end stage renal disease
- ejection fraction
- multidrug resistant
- newly diagnosed
- chronic kidney disease
- left ventricular assist device
- healthcare
- hematopoietic stem cell
- staphylococcus aureus
- primary care
- peritoneal dialysis
- public health
- stem cells
- gram negative
- big data
- cystic fibrosis
- high dose
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- cell therapy
- acinetobacter baumannii
- artificial intelligence
- replacement therapy
- deep learning
- mechanical ventilation